PURPOSE: New agents are required for the patients with epithelial ovarian cancer (EOC) who progress after first and second line of the treatment. Tumor vasculature targeted agents are potentially active in EOC. We aimed to assess the activity of sorafenib in patients with recurrent EOC who had received two prior therapies. PATIENTS AND METHODS: A phase II non-randomized, open-label, single-arm study aimed to assess the efficacy, safety and tolerance of sorafenib monotherapy as a third line therapy in patients with EOC or primary peritoneal cancer (PPC). Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle. The primary end point of the study was to demonstrate the progression free survival (PFS). RESULTS: Eleven patients were enrolled. The median number of cycles was two. Among the 11 patients eligible for efficacy analysis, no patients experienced a partial response or complete response or stable disease lasting longer than 6 months according to RECIST criteria. Thus, the trial stopped at the end of the first stage of study design. The median PFS was 2.00 months (95% CI, 1,80-3,90). The median OS was 11.78 months (95% CI, 7.66 to 15.39). There were no grade 4 toxicities and few grade 3 toxicities. CONCLUSION: Sorafenib fails to achieve sufficient objective response or sustained disease stabilization as third-line treatment for EOC.
PURPOSE: New agents are required for the patients with epithelial ovarian cancer (EOC) who progress after first and second line of the treatment. Tumor vasculature targeted agents are potentially active in EOC. We aimed to assess the activity of sorafenib in patients with recurrent EOC who had received two prior therapies. PATIENTS AND METHODS: A phase II non-randomized, open-label, single-arm study aimed to assess the efficacy, safety and tolerance of sorafenib monotherapy as a third line therapy in patients with EOC or primary peritoneal cancer (PPC). Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle. The primary end point of the study was to demonstrate the progression free survival (PFS). RESULTS: Eleven patients were enrolled. The median number of cycles was two. Among the 11 patients eligible for efficacy analysis, no patients experienced a partial response or complete response or stable disease lasting longer than 6 months according to RECIST criteria. Thus, the trial stopped at the end of the first stage of study design. The median PFS was 2.00 months (95% CI, 1,80-3,90). The median OS was 11.78 months (95% CI, 7.66 to 15.39). There were no grade 4 toxicities and few grade 3 toxicities. CONCLUSION:Sorafenib fails to achieve sufficient objective response or sustained disease stabilization as third-line treatment for EOC.
Authors: Silvia R Graziani; Carolina G Vital; Aleksandra T Morikawa; Brigitte M Van Eyll; Hezio J Fernandes Junior; Roberto Kalil Filho; Raul C Maranhão Journal: Med Oncol Date: 2017-07-29 Impact factor: 3.064
Authors: Anita Schwandt; Vivian E von Gruenigen; Robert M Wenham; Heidi Frasure; Susan Eaton; Nancy Fusco; Pingfu Fu; John J Wright; Afshin Dowlati; Steven Waggoner Journal: Invest New Drugs Date: 2014-03-12 Impact factor: 3.850
Authors: Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly Journal: Clin Cancer Res Date: 2013-07-30 Impact factor: 12.531
Authors: Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood Journal: Cancer Metastasis Rev Date: 2015-03 Impact factor: 9.264
Authors: Nilofer Azad; Minshu Yu; Ben Davidson; Peter Choyke; Clara C Chen; Bradford J Wood; Aradhana Venkatesan; Ryan Henning; Kathy Calvo; Lori Minasian; Daniel C Edelman; Paul Meltzer; Seth M Steinberg; Christina M Annunziata; Elise C Kohn Journal: Mol Cell Proteomics Date: 2013-02-28 Impact factor: 5.911
Authors: James Mattina; Nathalie MacKinnon; Valerie C Henderson; Dean Fergusson; Jonathan Kimmelman Journal: Cancer Res Date: 2016-06-03 Impact factor: 12.701